Timing Pharmaceutical Co Ltd

Timing Pharmaceutical Co Ltd has a debt-to-equity ratio of 0.79, indicating a moderate reliance on debt financing, and a current ratio of 1.15, suggesting limited short-term liquidity. The company's free cash flow of TWD 68,023,000 and operating cash flow of TWD 262,593,000 indicate positive cash generation, though its cash and equivalents are reported at zero, raising concerns about immediate liquidity. The company's return on equity of 5.6% and return on assets of 2.06% are below the typical thresholds for pharmaceutical firms, which often aim for higher returns due to the capital-intensive nature of R&D and production. These metrics suggest that Timing Pharmaceutical Co Ltd is underperforming relative to industry expectations in terms of profitability and asset utilization. Timing Pharmaceutical Co Ltd's revenue is concentrated in a single business segment, with no disclosed geographic diversification, which increases exposure to regional market risks. The absence of segment or geographic breakdown in the financial data limits the ability to assess the company's risk profile in detail. The company's growth trajectory is unclear, as no specific revenue growth rates or future projections are provided in the available data. However, the operating income of TWD 53,200,000 and net income of TWD 60,458,000 suggest a stable but modest performance in the most recent reporting period. The risk assessment indicates a medium liquidity risk and a low dilution risk, with the key flag being the negative net cash position after subtracting total debt. The company's capital structure, with long-term debt of TWD 854,472,000 and total equity of TWD 1,079,326,000, suggests a balanced but cautious approach to financing. No recent events, such as filings or transcripts, are disclosed in the available data, which limits the ability to assess the company's strategic direction or external pressures.